Laboratory Corp of America Holdings Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Laboratory Corp of America Holdings Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Laboratory Corp of America Holdings were recently set by nine distinguished experts, with an average mark of $241.00. If it reached this goal, it would represent a potential upside of approximately 21.5% from the previous closing price in April, 2024. The high end is $262.00, and the low is $213.00. If you're considering investing in LH stock, it's essential to look at its competitors, too.
21.50% Upside
Laboratory Corp of America Holdings Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Laboratory Corp of America Holdings's Price has gone down from $304.28 to $0.00 – a 100.00% drop. For next year, analysts predict Fair Value of $259.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Laboratory Corp of America Holdings's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$135.42 | Buy/Sell | $141.17 | 7.07% |
| NTRA Stock Forecast | Natera | Outperform |
7
|
$91.28 | Buy/Sell | $74.41 | 12.84% |
| RDNT Stock Forecast | RadNet | Outperform |
15
|
$48.85 | Buy/Sell | $40.20 | 7.47% |
| NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$13.85 | Buy/Sell | $20.09 | 44.40% |
| OPK Stock Forecast | OPKO Health | Outperform |
8
|
$1.01 | Buy/Sell | $6.70 | 296.04% |
Laboratory Corp of America Holdings Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Laboratory Corp of America Holdings's Revenue has gone down from $13.98B to $12.16B – a 13.00% drop. For next year, analysts predict Revenue of $16.35B, which would mean an increase of 34.42%. Over the next seven years, experts predict that Laboratory Corp of America Holdings's Revenue will grow at a rate of 34.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FLGT Stock Forecast | Fulgent Genetics | Hold |
16
|
$20.03 | Buy/Sell | $31.50 | 24.81% |
| CSTL Stock Forecast | Castle Biosciences | Buy |
9
|
$19.51 | Buy/Sell | $31.56 | 69.14% |
| FONR Stock Forecast | FONAR | - |
16
|
$22.17 | Buy/Sell | $0.00 | -100.00% |
.jpg)
Laboratory Corp of America Holdings Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Laboratory Corp of America Holdings's Dividend per Share has grown, rising from $2.16 to $2.88 – a growth of 33.33%. According to 7 analysts, Laboratory Corp of America Holdings's Dividend per Share will fall by 42.71% in the next year, reaching $1.65. Professionals believe that By 2030, Laboratory Corp of America Holdings's Dividend per Share will fall to $2.40 – a 16.81% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ENZ Stock Forecast | Enzo Biochem | - |
8
|
$1.36 | Buy/Sell | $5.50 | -100.00% |
| CGIX Stock Forecast | Cancer Genetics | - |
0
|
$0.00 | Buy/Sell | $90.00 | 0.00% |
| AKUM.Q Stock Forecast | Akumin | - |
11
|
$0.38 | Buy/Sell | $0.55 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STRR Stock Forecast | Star Equity Holdings | Buy |
10
|
$0.88 | Buy/Sell | $5.00 | 468.18% |
| PCHM Stock Forecast | PharmChem | - |
0
|
$3.57 | Buy/Sell | $0.00 | -100.00% |
| PMD Stock Forecast | Psychemedics | - |
0
|
$3.10 | Buy/Sell | $32.00 | -100.00% |
Laboratory Corp of America Holdings EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Laboratory Corp of America Holdings's EBITDA has decreased by 54.94%, going from $3.59B to $1.62B. In the next year, analysts believe that EBITDA will reach $3.10B – an increase of 91.45%. For the next seven years, the forecast is for EBITDA to grow by 54.60%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBSC Stock Forecast | CB Scientific | - |
0
|
$0.06 | Buy/Sell | $0.00 | -100.00% |
| IDXG Stock Forecast | Interpace Biosciences | - |
0
|
$1.06 | Buy/Sell | $11.00 | -100.00% |
| NVTA Stock Forecast | Invitae | - |
4
|
$0.00 | Buy/Sell | $0.71 | 0.00% |
Laboratory Corp of America Holdings EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Laboratory Corp of America Holdings's EBIT has decreased from $3.09B to $1.11B – a 63.98% drop. For the next year, analysts predict that EBIT will reach $2.61B – an increase of 134.85%. Over the next seven years, experts believe that Laboratory Corp of America Holdings's EBIT will grow at a rate of 140.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OTCPK:RNVA Stock Forecast | Rennova Health | - |
0
|
0.00 | Buy/Sell | 0.00 | 0.00% |
| MEDD Stock Forecast | Medical Imaging | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| RIGH Stock Forecast | Bud Genius | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
Laboratory Corp of America Holdings EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Laboratory Corp of America Holdings's EPS has gone down from $23.94 to $0.00 – a 100.00% drop. For next year, analysts predict EPS of $20.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Laboratory Corp of America Holdings's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EVIO Stock Forecast | EVIO | - |
0
|
$0.00 | Buy/Sell | $2.00 | 0.00% |
| BTW Stock Forecast | Aeon Global Health | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| RGDX.Q Stock Forecast | Response Genetics, Inc | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
Site Navigation
.jpg)